Possible benefit of nuts in type 2 diabetes

被引:72
|
作者
Jenkins, David J. A. [1 ,2 ]
Hu, Frank B. [4 ,5 ]
Tapsell, Linda C. [6 ]
Josse, Andrea R. [1 ,2 ]
Kendall, Cyril W. C. [1 ,2 ,3 ]
机构
[1] St Michaels Hosp, Clin Nutr & Risk Factor Modificat Ctr, Toronto, ON M5C 2T2, Canada
[2] Univ Toronto, Fac Med, Dept Nutr Sci, Toronto, ON M5S 3F2, Canada
[3] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK S7N 5C9, Canada
[4] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
[5] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[6] Univ Wollongong, Natl Ctr Excellence Funct Food, Wollongong, NSW 2522, Australia
来源
JOURNAL OF NUTRITION | 2008年 / 138卷 / 09期
关键词
D O I
10.1093/jn/138.9.1752S
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Nuts, including peanuts, are now recognized as having the potential to improve the blood lipid profile and, in cohort studies, nut consumption has been associated with a reduced risk of coronary heart disease (CHID). More recently, interest has grown in the potential value of including nuts in the diets of individuals with diabetes. Data from the Nurses Health Study indicates that frequent nut consumption is associated with a reduced risk of developing diabetes and cardiovascular disease. Randomized controlled trials of patients with type 2 diabetes have confirmed the beneficial effects of nuts on blood lipids also seen in nondiabetic subjects, but the trials have not reported improvement in Alp or other glycated proteins. Acute feeding studies, however, have demonstrated the ability of nuts, when eaten with carbohydrate (bread), to depress postprandial glycemia. Furthermore, there was evidence of reduced postprandial oxidative stress associated with nut consumption. In terms of dietary composition, nuts have a good nutritional profile, are high in monounsaturated fatty acids (MUFA) and PUFA, and are good sources of vegetable protein. Incorporation of nuts in the diet may therefore improve the overall nutritional quality of the diet. We conclude that there is justification to consider the inclusion of nuts in the diets of individuals with diabetes in view of their potential to reduce CHD risk, even though their ability to influence overall glycemic control remains to be established.
引用
收藏
页码:1752S / 1756S
页数:5
相关论文
共 50 条
  • [31] Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit
    Papaetis, Georgios S.
    Orphanidou, Dora
    Panagiotou, Themistoklis N.
    CURRENT DRUG TARGETS, 2011, 12 (10) : 1498 - 1512
  • [32] Type 2 Diabetes with Albuminuria Heart and Kidneys benefit from nsMRA
    不详
    DIABETES STOFFWECHSEL UND HERZ, 2024, 33 (05):
  • [33] Drug Combo Adds No Benefit in Patients with Type 2 Diabetes Reply
    George, Christa M.
    Bruijn, Lucy L.
    Will, Kayley
    Howard-Thompson, Amanda
    AMERICAN FAMILY PHYSICIAN, 2016, 93 (06) : 436 - 438
  • [34] Renal Benefit of Dapagliflozin Therapy in Hyperfiltering Type 2 Diabetes Patients
    Baskoy, Gozde
    Qin, Yuejuan
    Cersosimo, Eugenio
    Solis-Herrera, Carolina
    Adams, John M., III
    Defronzo, Ralph A.
    Triplitt, Curtis L.
    DIABETES, 2023, 72
  • [35] Exercise precision medicine for type 2 diabetes: Targeted benefit or risk?
    Le, Shenglong
    Schumann, Moritz
    Lei, Siman
    Yao, Wu
    Cheng, Sulin
    SPORTS MEDICINE AND HEALTH SCIENCE, 2023, 5 (02) : 146 - 150
  • [36] Antidiabetic drugs in type 2 diabetes: reappraising the benefit/risk balance
    Boussageon, Remy
    Pouchain, Denis
    Renard, Vincent
    EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE, 2014, 25 (115): : 238 - 243
  • [37] BENEFIT OF BENFLUOREX IN TYPE-2 DIABETES - CLINICAL-DATA
    BRUN, JM
    PRESSE MEDICALE, 1992, 21 (28): : 1344 - 1352
  • [38] A risk-benefit assessment of metformin in type 2 diabetes mellitus
    Howlett, HCS
    Bailey, CJ
    DRUG SAFETY, 1999, 20 (06) : 489 - 503
  • [39] Possible impact of electronegative LDL on atherosclerosis in type 2 diabetes
    Tamura, Kouichi
    Haruhara, Kotaro
    Azushima, Kengo
    Tokita, Yasuo
    Wakui, Hiromichi
    ATHEROSCLEROSIS, 2017, 265 : 253 - 255
  • [40] Insulin Therapy in Type-2-Diabetes- as late as possible!
    Jacob, Stephan
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (08) : 579 - +